Segmented Linear Mixed Model Analysis Reveals Association of the APOE ε4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression
Manuscript Number:
21-0434R1
Author(s):
X. Richard Chen, Martin Sadowski, Yongzhao Shao
Disclosures
X. Richard Chen
Nothing to Disclose
Martin Sadowski
Consulting Fees:
Consulting fees: Adept Field Solutions, PA USA; Biogen Inc, MA, USA; Decision Resource Group) MA, USA; Gerson Lehrman Group) NY, USA; Guidepoint Consulting, NY, USA; Noble Insights, Inc. NJ, USA
Sponsors:
The site principal investigator at New York University Grossman School of Medicine for Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 and 3 studies, which support is derived from NIA grant U01 AG024904 PI M Weiner
Patents/Royalties
U.S. Patent No. 9,364,449 unlicensed
Grants
Agency:
Biogen Inc, MA - clinical trial site for AD drugs
Dates:
2015-ongoing
Agency:
Eisai Co., Ltd - clinical trial site for AD drugs
Dates:
2020-ongoing
Agency:
Novartis Pharma - clinical trial site for AD drugs
Dates:
2016-ongoing
Agency:
Suven Life Sciences Ltd. - clinical trial site for AD drugs
Dates:
2016-2021
Agency:
Merck Sharp & Dohme Corp.- clinical trial site for AD drugs
Dates:
2014-2020
Agency:
Neurotrack Technologies Inc. - Industry Research Grant
Dates:
2014-2019
Agency:
Janssen Research and Development- Industry Research Grant
Dates:
2014-2019
Agency:
Eli Lilly & Company - clinical trial site for AD drugs